U. Wedding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
U. Wedding has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
A Klippstein
1 shared publicationA. Hoffmann
1 shared publicationK Höffken
1 shared publicationK. Hoffken
Aus der Klinik und Poliklinik für Innere Medizin II der Friedrich‐Schiller‐Universität, Jena, Deutschland
1 shared publicationK. Höffken
1 shared publication- Katrin Farker
Institute for Hospital Pharmacy, University Center for Pharmacotherapy and Pharmacoeconomics, Jena University Hospital, Jena, Germany
1 shared publication
Latest Publications
- 11 September 2008
- Published by Georg Thieme Verlag KG in Zeitschrift für Palliativmedizin
- Vol. 9 (03)
Welcher Patient mit Krebserkrankung sollte primär palliativmedizinisch behandelt werden?
- 11 September 2008
- Published by Georg Thieme Verlag KG in Zeitschrift für Palliativmedizin
- Vol. 9 (03)
Welcher Patient mit Krebserkrankung sollte primär palliativmedizinisch behandelt werden?
- 1 March 2006
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 44 (3) , 128-134
Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxaliplatin, 5-FU and sodium folinate in a pilot investigat
To analyze in a pilot study the association between the pharmacokinetics of chronomodulated administered oxaliplatin and non-hematological toxicity in patients with metastatic gastrointestinal cancer. 16 patients received a 4-day chemotherapeutic regimen consisting of a 12-h chronomodulated infusion of oxaliplatin (25 mg/m2) followed by a 12-h chronomodulated infusion of 5-fluorouracil (750 mg/m2) and sodium folinate (150 mg/m2) daily. Plasma pharmacokinetics of oxaliplatin, measured as ultrafiltrable platinum, were determined. Pharmacokinetics and non-hematological adverse events could be assessed in all patients included in the study. Pharmacokinetic parameters showed moderate interpatient variability. The occurrence of nausea and vomiting, but not diarrhea, was significantly associated with the pharmacokinetics of ultrafiltrable platinum. Thus, increased AUC values were observed in patients who experienced nausea or vomiting. No differences in pharmacokinetic parameters were found between patients with and without oxaliplatin-induced neurotoxicity or the other selected non-hematological toxicities. The preliminary results in this pilot study suggest an association between pharmacokinetics of ultrafiltrable platinum and non-hematological toxicity such as nausea and vomiting. Furthermore, although the sample size is limited, systemic exposure to ultrafiltrable platinum appears to predict the risk of non-hematological toxicity in patients treated with chronomodulated oxaliplatin combined with 5-FU and FS.
- 1 March 2006
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 44 (3) , 128-134
Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxaliplatin, 5-FU and sodium folinate in a pilot investigat
To analyze in a pilot study the association between the pharmacokinetics of chronomodulated administered oxaliplatin and non-hematological toxicity in patients with metastatic gastrointestinal cancer. 16 patients received a 4-day chemotherapeutic regimen consisting of a 12-h chronomodulated infusion of oxaliplatin (25 mg/m2) followed by a 12-h chronomodulated infusion of 5-fluorouracil (750 mg/m2) and sodium folinate (150 mg/m2) daily. Plasma pharmacokinetics of oxaliplatin, measured as ultrafiltrable platinum, were determined. Pharmacokinetics and non-hematological adverse events could be assessed in all patients included in the study. Pharmacokinetic parameters showed moderate interpatient variability. The occurrence of nausea and vomiting, but not diarrhea, was significantly associated with the pharmacokinetics of ultrafiltrable platinum. Thus, increased AUC values were observed in patients who experienced nausea or vomiting. No differences in pharmacokinetic parameters were found between patients with and without oxaliplatin-induced neurotoxicity or the other selected non-hematological toxicities. The preliminary results in this pilot study suggest an association between pharmacokinetics of ultrafiltrable platinum and non-hematological toxicity such as nausea and vomiting. Furthermore, although the sample size is limited, systemic exposure to ultrafiltrable platinum appears to predict the risk of non-hematological toxicity in patients treated with chronomodulated oxaliplatin combined with 5-FU and FS.
- 1 April 2002
- Published by Wiley in Wiener Medizinische Wochenschrift
- Vol. 152 (7-8) , 166-169
Einfuhrung in die geriatrische Onkologie
- 1 April 2002
- Published by Wiley in Wiener Medizinische Wochenschrift
- Vol. 152 (7-8) , 166-169
Einfuhrung in die geriatrische Onkologie